Neurol. praxi. 2022;23(2):115-119 | DOI: 10.36290/neu.2021.084

Treatable CNS disorders with brain metal accumulation

MUDr. Petr Dušek
Neurologická klinika a Centrum klinických neurověd, Univerzita Karlova v Praze
1. lékařská fakulta a Všeobecná fakultní nemocnice v Praze

Some neurological diseases caused by accumulation of iron in CNS are treatable. If the initiation of treatment is early, neurological symptoms may be reversibile. The best results are achieved when the treatment is started before the manifestation of neuro­logical symptoms. In this chapter we summarize the clinical features, diagnosis and treatment strategies in treatable diseases with the accumulation of copper (Wilson's disease), calcium (hypoparathyroidism), manganese (SLC30A10 and SLC39A14 transporter deficiency) and iron (aceruloplasminaemia).

Keywords: Wilson disease, neurodegeneration with brain iron accumulation, manganism, hypoparathyroidism.

Received: October 15, 2021; Revised: October 15, 2021; Accepted: October 31, 2021; Prepublished online: October 31, 2021; Published: April 21, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dušek P. Treatable CNS disorders with brain metal accumulation. Neurol. praxi. 2022;23(2):115-119. doi: 10.36290/neu.2021.084.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aggarwal S, Kailash S, Sagar R, et al. Neuropsychological dys­function in idiopathic hypoparathyroidism and its relation­ship with intracranial calcification and serum total cal­cium. Eur J Endocrinol. 2013;168(6):895-903. Go to original source... Go to PubMed...
    2. Czlonkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers. 2018;4(1):21. Go to original source... Go to PubMed...
    3. Dusek P, Litwin T, Czlonkowska A. Neurologic impairment in Wilson disease. Ann Transl Med. 2017;7(Suppl 2):S64. Go to original source... Go to PubMed...
    4. Dusek P, Schneider SA, Aaseth J. Iron chelation in the treat­ment of neurodegenerative diseases. J Trace Elem Med Biol. 2016;38:81-92. Go to original source... Go to PubMed...
    5. Dusek P, Smolinski L, Redzia-Ogrodnik B, et al. Semiquantitative Scale for Assessing Brain MRI Abnormalities in Wilson Disease: A Validation Study. Mov Disord. 2020;35(6):994-1001. Go to original source... Go to PubMed...
    6. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012;56(3):671-685. Go to original source... Go to PubMed...
    7. Goswami R, Sharma R, Sreenivas V, et al. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf). 2012;77(2):200-206. Go to original source...
    8. Klopstock T, Tricta F, Neumayr L, et al. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol. 2019;18(7):631-642. Go to original source... Go to PubMed...
    9. Kostic VS, Petrovic IN. Brain Calcification and Movement Disorders. Curr Neurol Neurosci. 2017; Rep 17(1):2. Go to original source... Go to PubMed...
    10. Mannstadt M, Bilezikian JP, Thakker RV, et al. Hypoparathyroidism. Nat Rev Dis Primers. 2017;3:17055. Go to original source... Go to PubMed...
    11. Marchi G, Busti F, Lira Zidanes A, et al. Aceruloplasminemia: A Severe Neurodegenerative Disorder Deserving an Early Diagnosis. Front Neurosci. 2019;13:325. Go to original source... Go to PubMed...
    12. Przybylkowski A, Gromadzka G, Chabik G, et al. Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson's disease. Funct Neurol. 2014;29(1):23-29. Go to original source... Go to PubMed...
    13. Quadri M, Federico A, Zhao T, et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012;90(3):467-477. Go to original source... Go to PubMed...
    14. Tuschl K, Clayton PT, Gospe SM Jr., et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet. 2012;90(3):457-466. Go to original source... Go to PubMed...
    15. Tuschl K, Meyer E, Valdivia LE, et al. Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia. Nat Commun. 2016;7:11601. Go to original source... Go to PubMed...
    16. Vrabelova S, Letocha O, Borsky M, Kozak L. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. Mol Genet Metab. 2005;86(1-2):277-285. Go to original source... Go to PubMed...
    17. Vroegindeweij LHP, Boon AJW, Wilson JHP, Langendonk JG. Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports. Orphanet J Rare Dis. 2020;15(1):105. Go to original source... Go to PubMed...
    18. Zaki MS, Issa MY, Elbendary HM, et al. Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation. Clin Genet. 2018;93(4):905-912. Go to original source... Go to PubMed...
    19. Zimbrean P, Seniow J. Cognitive and psychiatric symptoms in Wilson disease. Handbook of clinical neurology/edited by P.J. Vinken and G.W. Bruyn. 2017;142:121-140. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.